KR20100097647A - Skin compositions for exteral application containing dalbergiae odoriferae lignum extract - Google Patents

Abstract

PURPOSE: An external use skin composition containing Dalbergiae odoriferae Lignum extract is provided to suppress the production of interleukin-4 and excessive proliferation of T-lymphocytes. CONSTITUTION: A cosmetic composition for treating T lymphocyte-mediated dermal immune diseases contains 0.001-10 weight% of Dalbergiae odoriferae Lignum extract as an active ingredient. The T lymphocyte-mediated dermal immune diseases include atopic dermatitis, contact dermatitis, or psoriasis. A pharmaceutical composition for treating T lymphocyte-mediated dermal immune diseases contains Dalbergiae odoriferae Lignum extract as an active ingredient. A dose of the pharmaceutical composition is 0.001-100mg/kg a day.

Description

Skin composition for exteral application containing kangjinhyang extract {Dkinbergia odoriferae Lignum extract}

The present invention relates to a composition for external application for skin containing herbal extracts, and more particularly, Acanthopanacis Cortex ), Dalbergiae odoriferae Lignum ), Phragmitis Rhizoma ), Angelicae Gigantis Radix ), Thujae Semen , Tribuli Semen ), Atractylodis Rhizoma alba ), eruption ( Zedoariae Rhizoma ), Spirodelae Herba ), casualty ( Torilidis Fructus and Dendrobii Herba ) relates to a composition containing at least one extract selected. The external preparation composition for skin of the present invention improves the symptoms of various skin diseases caused by T lymphocyte mediated immune response, specifically atopic dermatitis, contact dermatitis, psoriasis, etc., and furthermore, for the treatment and prevention of these skin diseases. Can be used.

Atopic Dermatitis is a complex of skin that is characterized by a combination of symptoms such as strong pruritus, dryness, severe keratinization, torn head, dandruff, erythema and swelling, skin cracks, severe rashes, eczema, and thyroiditis. It is an abnormal syndrome. In many cases, it is a chronic disease that lasts for more than 10 years and causes great inconvenience in long-term life. In the past, infants and infants started in the early stages of development and their condition gradually improved and disappeared before the age of 7-8 years. However, since the 1970s, the incidence rate has increased year by year due to the pollution and environmental pollution caused by the rapid industrialization, and the symptoms continue to adolescence and adulthood, and become more severe or newly developed after adolescence. Symptoms are accompanied by strong itching and skin irritation, and excessive secretion of histamine is a major cause of itching. When the skin is scratched due to itching, erythema or eczema appears, and in severe cases, the skin may be peeled off or the lichen may become thickened.

Many studies and information on the cause of atopic dermatitis have been presented until recently, but the exact pathology and effective treatment have not yet been established due to the complexity of the disease itself and conflicting research data. Due to these problems, the atopic dermatitis treatments that have been developed to date help to control symptoms to an appropriate level rather than the fundamental treatment such as steroid preparations, oral antihistamines, hydroxyquinoline, tar preparations, and hypoallergenic moisturizers. Products dominate. However, none of the drugs developed to date fully meet the needs of patients. Until recently, topical steroid preparations have been the main dominant agents for treating atopic dermatitis, but there is an urgent need for development of safer nonsteroidal atopic dermatitis treatments without side effects due to resistance expression and safety problems during long-term use.

Recently, it has been found that abnormally activated immune responses, such as hyperactivity of T lymphocytes and hypersensitivity of IgE, are one of the main causes of atopic dermatitis, contact dermatitis, and psoriasis disease. Attempts to treat these skin diseases by suppressing the response have attracted attention.

There are many types of cytokines that control T cell mediated immune responses, but interleukin-2 and interleukin-4 play important roles in the pathology of atopic dermatitis. Interleukin-2 is a cytokine produced in the early stages of T cell activation and strongly triggering an immune response by stimulating Th cells.

In addition, it has been found that interleukin-4, which has recently been of great interest in the pathogenesis of atopic dermatitis, induces a disproportionate activation of Th2 cells, a characteristic pathology of atopic dermatitis, in particular. At the same time, interleukin-4 is a key cytokine that stimulates B cells to increase IgE production, thereby promoting histamine secretion by mast cells, leading to atopic reactions such as erythema, redness, and itching. Literature describing the fact that immune responses, such as hyperactivity of T lymphocytes and hypersensitivity from IgE, is associated with atopic dermatitis, contact dermatitis and psoriasis disease is known. Leung D and Bieber T. Atopic Dermatitis. Lancet 2003, 361: 151-160, Galli E, Cicconi R, Rossi P, Casati A, Brunetti E, and Mancino G. Atopic Dermatitis: Molecular Mechanisms, Clinical Aspects and New Therapeutical Approaches. Current Molecular Medicine 2003, 3: 127-138, Christophers E. Psoriasis-epidemiology and clinical spectrum. Clinnical Experimental Dermatology 2001, 26 (4): 314-320].

Thus, substances capable of simultaneously inhibiting the production of interleukin-2 and interleukin-4 and the final proliferation of T cells, the end result of these cytokine reactions, may provide better efficacy for the treatment of atopic dermatitis than common immunosuppressive agents. It can be seen that.

Therefore, the inventors of the present invention, while searching for a way to control the abnormally activated immune response in the skin, thorns, gangjinhyang, Rooteun, Angelica, Baekjain, Baekji-ryeon, Baekchul, Bleach, Bupyeongcho, casualty and Seokgok extract T lymphocytes Suppresses the production of interleukin-2, a key cytokine in the mediated immune response, and interleukin-4, a T lymphocyte cytokine that stimulates IgE production, and also inhibits excessive proliferation of T lymphocytes It has been found that the present invention has the effect of completing the present invention.

Therefore, an object of the present invention, by containing one or more of the herbal extracts as an active ingredient, to suppress abnormally activated T lymphocyte-mediated immune response to improve the symptoms of atopic dermatitis, contact dermatitis and psoriasis It is to provide a safe and effective external preparation composition for skin.

In order to achieve the above object, the present invention provides a cosmetic composition and pharmaceutical composition for improving T lymphocyte-mediated skin immune disease containing a strong extract as an active ingredient.

Composition containing one or more extracts selected from the group consisting of prickly scab, Kang Jin-hyang, Root-geun, Angelica, white porcelain, Baekji-ryeon, Baekchul, Bulge, Bupyeong-cho, casualty and Seokgok inhibit the production of interleukin-2 and interleukin-4 In addition, it suppressed the proliferation of T lymphocytes and exhibited no specific toxicity to mouse spleen lymphocytes, keratinocytes and fibroblasts. Therefore, the composition according to the present invention is very safe and effectively inhibits the T lymphocyte mediated immune response. Therefore, it can be used as a composition capable of treating or preventing atopic dermatitis, contact dermatitis, psoriasis and the like which are skin diseases related to excessive T lymphocyte mediated immune response.

In order to achieve the above object, the composition for external application for skin according to the present invention is an extract of one or more herbal medicines selected from thorny stems, gangjinhyang, Root-geun, Angelica, Baekjain, Baekjiryeo, Baekchul, Byeonpyeong, Bupyeongcho, Saengsaeng and Seokgok as active ingredients. It is characterized by containing.

In the external preparation composition for skin according to the present invention, the herbal extract is characterized in that it is contained in an amount of 0.001 to 10% by weight, preferably 0.01 to 5% by weight in the total composition.

The external preparation composition for skin of the present invention improves the symptoms of various skin diseases caused by T lymphocyte mediated immune response, specifically atopic dermatitis, contact dermatitis, psoriasis, etc., and furthermore, for the treatment and prevention of these skin diseases. Can be used. To this end, the external preparation composition for skin of the present invention may be provided as a pharmaceutical composition for the purpose of treating and preventing the skin disease, and may also be provided as a functional cosmetic composition for the purpose of improving the symptoms of the skin disease.

Hereinafter, the present invention will be described in more detail.

The herbal extracts used in the external preparation composition for skin of the present invention, as will be described in detail below, are herbal medicines that have been used for the purpose of improving and treating symptoms of various diseases since ancient times, and have been proven herbal medicines for human safety.

Acanthopanacis used in the present invention Cortex ) Acanthopanax , a deciduous shrub belonging to the Araliaceae senticosus ) is used to remove desquamation , blood and liver and kidneys.

Dalbergiae odoriferae Lignum is a deciduous tree belonging to the leguminosae , Dalbergia. odorifera T. Chen) As a core of roots, it is used for selfishness, hemostasis, blood removal, and pain.

Phragmitis Rhizoma is the root of Phragmites communis TRIN, a perennial herb of the Poaceae family .

Angelicae Gigantis Radix) is a perennial plant of the Apiaceae (Umbelliferae) True Angelica (Angelica As the root of gigas NAKAI), it is used for the purpose of wind, blood, colloquial blood, landscaping and soothing.

Thujae Semen is a species of evergreen arboraceae , Biota orientalis (L) ENDL, in the Cupressaceae family.

Tribuli Semen is a fruit of the annual herb, Tribulus terrestris , of the Zygophyllaceae family. It is used for the purpose of lowering blood pressure, diuresis and headache control.

Atractylodis Rhizoma alba ) is a perennial herbaceous Atractylodes of the family Asteraceae ( Compositae ) macrocephala KOIDZ) and is used for the treatment of anorexia, bloating, edema, and arthritis.

Zedoariae Rhizoma is the root of Curcuma zedoaria (BERG.) Rosc., A perennial herb of the Zingiberaceae .

Bupyeongcho ( Spirodelae) Herba) is a perennial plant duckweed in excess of Bupyeong (Lemnaceae) (Spirodela polyrrhiza (L) SCHLEID) is used for the purpose of sweating, diuresis, clearing, detoxification, etc.

Casualties ( Torilidis Fructus) is an annual herbaceous earn casualties Apiaceae (Umbelliferae) (Cnidium The fruit of monnieri (L) CUSSON) is used for the purpose of treating wind, moist, insecticide and gynecological diseases.

Seokgok (Dendrobii Herba) is used as a sentinel of Orchidaceae (Orchidaceae) perennial plant of seokgok (Dendrobium moniliforme (L) SW) for the purpose, such as stomach, tonic, cheongyeol, boeum.

The herbal extract used as an active ingredient in the external preparation composition for skin of the present invention has been shown to be effective for improving and treating the symptoms of various diseases as described above, but the inhibitory effect on T lymphocyte-mediated immune responses desired in the present invention. Is not known at all, and it is stated that this is only disclosed by the present invention. In particular, it is not known that the herbal extracts have the effect of inhibiting the production of interleukin-2 and interleukin-4 and excessive proliferation of T lymphocytes, which are the main causes of atopic dermatitis, contact dermatitis and psoriasis.

The amount of the extract used in the present invention is in vitro ( in In vitro ) based on the experiment is 0.001 to 10% by weight, preferably 0.01 to 5% by weight relative to the total weight of the composition. If the extract content is less than 0.001% by weight, it is difficult to expect to act as an active ingredient, and if the extract content is more than 10% by weight, problems with formulation stability may occur. From this point of view, more preferably used in an amount of 0.01 to 5% by weight.

The external preparation composition for skin according to the present invention can be used for the purpose of improving the symptoms of the skin diseases such as atopic dermatitis, contact dermatitis or psoriasis, further treatment and prevention, and the formulation is not particularly limited. Do not. The external preparation composition for skin of the present invention may be provided as a functional cosmetic composition for the purpose of improving the symptoms of the aforementioned skin diseases, and may also be provided as a pharmaceutical composition for the purpose of treating and preventing the skin diseases.

When the present invention is provided as a functional cosmetic composition, for example, in a soft cosmetics, nourishing cosmetics, massage creams, nutrition creams, packs, gels, essences or formulations of skin adhesive type cosmetics, or lotions, ointments, gels, creams, It may be formulated into a transdermal dosage form such as a patch or spray.

In addition, when the present invention is provided in a pharmaceutical composition, the herbal extract may be used as it is or in the form of a pharmaceutically acceptable salt. The salt is not particularly limited as long as it is pharmaceutically acceptable, and for example, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, formic acid, acetic acid, tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, succinic acid, methanesulfonic acid , Acid addition salts formed by benzenesulfonic acid, toluenesulfonic acid, naphthalenesulfonic acid and the like can be used. In addition to acid addition salts, base addition salts such as sodium hydroxide, potassium hydroxide, triethylamine, tert-butylamine can also be used.

The pharmaceutical composition according to the present invention can be formulated by adding various auxiliaries used in medicine, such as carriers or other additives such as stabilizers, emollients, emulsifiers and the like, as long as they do not adversely affect the active ingredient.

In the pharmaceutical composition according to the present invention, the content of the herbal extracts described above may vary widely depending on the formulation and is in accordance with conventional methods.

Pharmaceutical compositions according to the invention may be administered parenterally, transdermal administration is preferred, in particular topical application is most preferred. It may be formulated in a conventional manner using solid or liquid excipients or diluents suitable for topical application. For example, it may be any suitable formulation such as ointment, cream, injection, powder, granules, tablets and the like.

The dosage of the pharmaceutical composition according to the present invention varies depending on the age, condition, and degree of disease of the patient, but preferably, it is 0.001 to 1000 mg / kg · day.

The pharmaceutical compositions according to the invention can be administered alone or in combination with other agents or together to assist other agents.

In addition, in the external preparation composition of each formulation, other components other than the above-mentioned essential components can be suitably selected and blended by those skilled in the art according to the formulation of the external preparation or the purpose of use.

Hereinafter, the configuration and effect of the present invention will be described in more detail with reference to Examples and Test Examples. However, the present invention is not limited only to these examples.

< Example  1> Herbal medicine  Preparation of Extract

After drying and grinding 1kg each of thorny ginseng, Kangjin-hyang, Nogeun, Angelica, Baekjain, Baekjiryeo, Baekchul, Bupyeongcho, Bupyeongcho, Casualty and Seokgok, add 4% of 95% ethanol in weight ratio (kg), and then at 80 ℃ for 2 hours. The active ingredient was extracted by heating. This was allowed to stand at room temperature for 1 day to precipitate impurities, and the filtrate was filtered twice using a filter paper and concentrated by completely evaporating using a reduced pressure evaporator.

< Test Example  1> Interleukin -2 production inhibitory effect

Concanavalin A, a mitogen that reacts by stimulating T lymphocytes to splenocytes of BALB / C mice, was added, followed by treatment of the extracts prepared in Example 1, respectively. The production inhibitory effect was measured.

Specifically, the mouse's spleen cells were placed in a 96-well microtiter plate containing RPMI medium containing 10% fetal bovine serum to 200,000 cells / well, and 2 µg / conconnavaline A was added. A ml concentration was added to activate T lymphocytes. Each composition was then treated according to the concentration of Table 1 below, and after 24 hours, the interleukin-2 released into the culture was quantified by ELISA (Enzyme-Linked Immunosorbent Assay) method. At this time, using only the concanavalin A and not treated with the composition as a control group to calculate the interleukin-2 production inhibition rate according to Equation 1 shown in Table 1 below.

Composition Concentration (%) Interleukin-2 production inhibition rate (%) Go away 0.001 57 Gangjin Hyang 0.001 81 Labor 0.001 24 Donkey 0.001 99 White porcelain 0.001 96 White back 0.001 20 Whiteness 0.001 96 Ejection 0.001 31 Bupyeongcho 0.001 11 Casualties 0.001 38 Seokgok 0.001 34 Control 0

As shown in Table 1, the herbal extract of the present invention was found to have the effect of inhibiting the production of interleukin-2 by activated T lymphocytes at low concentrations of 0.001%, respectively.

< Test Example  2> Interleukin -4 production inhibitory effect

Concanavalin A was added to splenocytes of BALB / C mice, and the extracts prepared in Example 1 were treated, respectively, to measure the effect of inhibiting the production of interleukin-4.

Specifically, in a 96-well plate incubator containing 10% fetal bovine serum RPMI medium, mouse spleen cells were added to 400,000 cells / well, and concanavalin A was added at a concentration of 4 μg / ml. Activated. Each composition was then treated to the concentrations in Table 2 below to quantify interleukin-4 liberated into culture after 36 hours by ELISA method. At this time, using only the concanavalin A and not treated with the composition as a control group to calculate the interleukin-4 production inhibition rate according to Equation 1 shown in Table 2 the results.

Composition Concentration (%) Interleukin-4 production inhibition rate (%) Go away 0.001 65 Gangjin Hyang 0.001 55 Labor 0.001 54 Donkey 0.001 96 White porcelain 0.001 70 White back 0.001 53 Whiteness 0.001 32 Ejection 0.001 54 Bupyeongcho 0.001 53 Casualties 0.001 20 Seokgok 0.001 27 Control 0

As shown in Table 2, the herbal extract of the present invention was found to have the effect of inhibiting the production of interleukin-4 by activated T lymphocytes at low concentrations of 0.001%, respectively.

< Test Example  3> T Lymphocyte  Schizoproliferation Inhibitory Effect

Concanavalin A was added to splenocytes of BALB / C mice, and the extracts prepared in Example 1 were treated, respectively, to determine the effect of inhibiting the proliferation of T lymphocytes.

Specifically, in a 96-well plate incubator containing 10% fetal bovine serum RPMI medium, spleen cells of the mouse were added to 200,000 cells / well, and concanavalin A was added at a concentration of 2 µg / ml to obtain T lymphocytes. Activated. Then, each composition was treated at the concentration of Table 3 below, followed by incubation for 72 hours, followed by further incubation for 12 hours by adding BrdU at a concentration of 5 μM. BrdU incorporated into proliferating T lymphocytes was quantified by ELISA method. At this time, using only the concanavalin A and the group not treated with the composition as a control group according to the above formula 1 calculated the inhibition rate of division of T lymphocytes and the results are shown in Table 3.

Composition Concentration (%) T lymphocyte proliferation inhibition rate (%) Go away 0.001 24 Gangjin Hyang 0.001 25 Labor 0.001 12 Donkey 0.001 98 White porcelain 0.001 19 White back 0.001 11 Whiteness 0.001 24 Ejection 0.001 51 Bupyeongcho 0.001 38 Casualties 0.001 25 Seokgok 0.001 62 Control 0

As shown in Table 3, the herbal extracts of the present invention were found to have an effect of inhibiting the proliferation of activated T lymphocytes at low concentrations of 0.001%, respectively.

< Test Example  4> HaCaT Cytotoxicity measurement

HaCaT cells, which are human keratinocyte cell lines, were treated with the extract prepared in Example 1 to determine the cytotoxicity of each composition.

Specifically, HaCaT cells were dispensed at 5000 cells / well in a 96-well plate incubator containing DMEM medium containing 10% fetal calf serum and incubated for 24 hours to allow cell attachment. Each composition was incubated for 24 hours by treatment at the concentration of Table 4 below, and then 50 μl / well of tetrazolium dye was added and further cultured for 4 hours. Formazan produced by living cells was quantified by dissolving in 150 μl / well of dimethyl sulfoxide and measuring the absorbance at 570 nm. Absorbance by lysed formazan is proportional to the number of living cells. In this case, using the group not treated with the composition as a control group according to Equation 1 to calculate the inhibition rate of HaCaT cell activity is shown in Table 4 the results.

Composition Concentration (%) HaCaT cell activity inhibition rate (%) Go away 0.001 7 Gangjin Hyang 0.001 5 Labor 0.001 3 Donkey 0.001 0 White porcelain 0.001 3 White back 0.001 One Whiteness 0.001 0 Ejection 0.001 0 Bupyeongcho 0.001 2 Casualties 0.001 One Seokgok 0.001 0 Control - 0

< Test Example  5> Cytotoxicity measurement on human fibroblasts

Human fibroblasts were treated with the extract prepared in Example 1 to determine the cytotoxicity of each composition.

Specifically, fibroblasts were plated at 5000 cells / well in 96-well plate culture medium containing DMEM medium containing 10% fetal calf serum and incubated for 24 hours to allow cell attachment. Each composition was incubated for 24 hours by treatment at the concentration of Table 5 below, and then 50 μl / well of tetrazolium dye was added and further cultured for 4 hours. Formazan produced by living cells was quantified by dissolving in 150 μl / well of dimethyl sulfoxide and measuring absorbance at 570 nm. At this time, the fibroblast activity inhibition rate was calculated according to Equation 1 using the group not treated with the composition, and the results are shown in Table 5 below.

Composition Concentration (%) Fibroblast Activity Inhibition Rate (%) Go away 0.001 0 Gangjin Hyang 0.001 2 Labor 0.001 0 Donkey 0.001 0 White porcelain 0.001 0 White back 0.001 0 Whiteness 0.001 0 Ejection 0.001 0 Bupyeongcho 0.001 0 Casualties 0.001 8 Seokgok 0.001 0 Control - 0

< Test Example  6> mice On splenocytes  Cytotoxicity Measurements for

The splenocytes of BALB / C mice were treated with the extract prepared in Example 1 to determine the cytotoxicity of each composition.

Specifically, in a 96-well plate incubator containing RPMI medium containing 10% fetal bovine serum, spleen cells of the mice were dispensed to 500,000 cells / well, and each composition was treated according to the concentration in Table 6 below. After incubation for 50 hours, 50 μl / well of tetrazolium dye was added and further incubated for 4 hours. Formazan produced by living cells was quantified by dissolving in 150 μl / well of dimethyl sulfoxide and measuring absorbance at 570 nm. At this time, the control group was treated with the composition as a control group according to the formula 1 to calculate the mouse splenocyte activity inhibition rate is shown in Table 6 the results.

Composition Concentration (%) Inhibition rate of splenocyte activity (%) Go away 0.001 0 Gangjin Hyang 0.001 7 Labor 0.001 2 Donkey 0.001 9 White porcelain 0.001 0 White back 0.001 2 Whiteness 0.001 9 Ejection 0.001 0 Bupyeongcho 0.001 0 Casualties 0.001 0 Seokgok 0.001 0 Control 0

From the results shown in Table 1, Table 2, and Table 3, it was found that the herbal extract of the present invention effectively inhibits T lymphocyte mediated immune responses such as interleukin-2, interleukin-4, and T lymphocyte division. As a result, the herbal extract of the present invention is expected to have an excellent effect in improving or preventing the symptoms of diseases such as atopic dermatitis, contact dermatitis, and psoriasis related to excessively activated T lymphocyte-mediated immune responses.

In addition, as shown in Table 4, Table 5, and Table 6, the herbal extract of the present invention did not show a noticeable toxicity for human keratinocyte cell lines HaCaT cells, human fibroblasts, mouse spleen cells for 24 hours. Therefore, it can be seen that the inhibitory effect of the T lymphocyte mediated immune response by the herbal extract of the present invention is not caused by the direct toxicity of the extracts. Furthermore, these extracts are found to be very safe against keratinocytes, fibroblasts, and immune cells that are directly affected by external skin application.

< Example  2-12 and Comparative example > Of skin external preparation (cream)  Produce

In order to use the composition according to the composition of the present invention as an external preparation, a composition containing the herbal extract of Example 1 was prepared with the composition shown in Table 7 below. For comparison, a cream formulation containing no herbal extract was used as a comparative example.

Compounding ingredient Example 2
(%) Example 3
(%) Example 4
(%) Example 5
(%) Example 6
(%) Example 7
(%) Purified water To 100 To 100 To 100 To 100 To 100 To 100 Prickly Pear Extract 0.1 - Gangjinhyang Extract 0.1 Root Extract 0.1 Angelica Extract 0.1 White porcelain extract - - - - 0.1 - White itch extract - - - - - 0.1 Vegetable Cured Oil 1.50 1.50 1.50 1.50 1.50 1.50 Stearic acid 0.60 0.60 0.60 0.60 0.60 0.60 Stearyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00 Glycerol Stearate 1.00 1.00 1.00 1.00 1.00 1.00 Polyglyceryl-10 Pentastearate & Behenyl Alcohol & Sodium Stearoyl Lactylate 1.00 1.00 1.00 1.00 1.00 1.00 Arakidil Behenyl Alcohol &
Arachidil Glucoside 1.00 1.00 1.00 1.00 1.00 1.00 Cetylaryl Alcohol & Cetearyl Glucoside 2.00 2.00 2.00 2.00 2.00 2.00 PEG-100 Stearate & Glycerolate & Propylene Glycol 1.50 1.50 1.50 1.50 1.50 1.50 Caprylic / Capric Triglycerides 11.00 11.00 11.00 11.00 11.00 11.00 Cyclomedicon 6.00 6.00 6.00 6.00 6.00 6.00 Triethanolamine 0.1 0.1 0.1 0.1 0.1 0.1 Compounding ingredient Example 8 (%) Example 9 (%) Example 10 (%) Example 11 (%) Example 12 (%) Comparative Example (%) Purified water To 100 To 100 To 100 To 100 To 100 To 100 White Extract 0.1 - - - - - Extract - 0.1 - - - - Bupyeongcho Extract - - 0.1 - - - Casualty extract - - - 0.1 - - Seokgok Extract - - - - 0.1 - Vegetable Cured Oil 1.50 1.50 1.50 1.50 1.50 1.50 Stearic acid 0.60 0.60 0.60 0.60 0.60 0.60 Stearyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00 Glycerol Stearate 1.00 1.00 1.00 1.00 1.00 1.00 Polyglyceryl-10 Pentastearate & Behenyl Alcohol & Sodium Stearoyl Lactylate 1.00 1.00 1.00 1.00 1.00 1.00 Arachidil Behenyl Alcohol & Arachidil Glucoside 1.00 1.00 1.00 1.00 1.00 1.00 Cetylaryl Alcohol & Cetearyl Glucoside 2.00 2.00 2.00 2.00 2.00 2.00 PEG-100 Stearate & Glycerolate & Propylene Glycol 1.50 1.50 1.50 1.50 1.50 1.50 Caprylic / Capric Triglycerides 11.00 11.00 11.00 11.00 11.00 11.00 Cyclomedicon 6.00 6.00 6.00 6.00 6.00 6.00 Triethanolamine 0.1 0.1 0.1 0.1 0.1 0.1

< Test Example  7> Atopic symptoms improvement test in human body

In order to confirm the effect of improving atopic symptoms by the composition of the present invention, the creams prepared in Comparative Examples and Examples 5 (Dang Quai), 8 (Exud), 9 (Bulge) and 11 (Stone) were applied to the panels. The degree of atopic dermatitis improvement was evaluated.

For 50 panelists who had symptoms of atopic dermatitis showing similar symptoms, each group of 10 persons was divided into 5 groups, and each composition of Table 7 below twice daily at a temperature of 24 to 26 ° C and a humidity of 75%. It was applied to the face for 12 weeks. At the end of the study, subjects were asked to complete a questionnaire and subjective efficacy evaluations were conducted. The questionnaire included symptoms of atopic dermatitis such as “pruritus”, “dryness”, “keratogenesis”, “dandruff”, “erythema”, “swelling”, “skin cracking”, “truth and eczema”, and “chorus” In the case of the above symptom, the degree of improvement for each symptom was evaluated and averaged to evaluate the effect of improving atopy symptoms for each individual.

The results are shown in Table 8.

Applicator Respondents (Personal) Markedly improved Improving No change worse Comparative example One 3 6 0 Example 5 (Dangui) 5 4 One 0 Example 8 (elution) 4 3 2 One Example 9 (closed) 4 5 One 0 Example 12 (Stone) 5 4 One 0

 From Table 8, it was confirmed that atopic dermatitis symptoms improved when the composition containing the herbal extract of the present invention was applied. In any case, there was no hypersensitivity reaction or side effects caused by the composition.

Claims (4)

Cosmetic composition for improving T lymphocyte-mediated skin immune disease containing Kang Jin-hyang extract as an active ingredient. The cosmetic composition according to claim 1, wherein the T lymphocyte-mediated immune disease is atopic dermatitis, contact dermatitis or psoriasis. The cosmetic composition according to claim 1 or 2, wherein the strong extract is contained in an amount of 0.001 to 10% by weight based on the total weight of the composition. A pharmaceutical composition for improving T lymphocyte-mediated skin immune disease containing Kangjin-hyang extract as an active ingredient.